Company news: Shilpa Medicare

| Updated on May 17, 2019 Published on May 17, 2019

Shilpa Medicare on Friday said it has received final approval from the US Food and Drug Administration for Docetaxel Injection in the strengths of 20 mg/mL, 80 mg/4 mL (20 mg/mL), and 160 mg/8 mL (20 mg/mL). Docetaxel Injection USP is a generic equivalent of reference listed drug (RLD) Taxotere used in the treatment of breast cancer, non-small cell lung cancer, prostate cancer, castric adenocarcinoma, and head and neck cancer as recommended in the label approved by the USFDA. Shares of Shilpa Medicare closed 0.90 per cent higher at ₹377 on the BSE.

Published on May 17, 2019
This article is closed for comments.
Please Email the Editor